Filing Details

Accession Number:
0001209191-10-047487
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-09-24 21:19:09
Reporting Period:
2010-09-24
Filing Date:
2010-09-24
Accepted Time:
2010-09-24 21:19:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1316175 Anthera Pharmaceuticals Inc ANTH Pharmaceutical Preparations (2834) 201852016
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1484729 Rachel A. Leheny C/o Anthera Pharmaceuticals, Inc.
25801 Industrial Boulevard, Suite B
Hayward CA 94545
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-09-24 250,000 $3.00 1,423,896 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Purchase Warrant Acquisiton 2010-09-24 100,000 $0.00 100,000 $3.30
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
100,000 2010-09-24 2015-09-24 No 4 P Indirect
Footnotes
  1. Represents a price per unit purchased in connection with a private offering under the terms of that certain Securities Purchase Agreement, dated September 20, 2010, between the Issuer and certain investors identified therein. Each unit consisted of one (1) share of common stock of the Issuer and a warrant to purchase 0.40 shares of common stock of the Issuer.
  2. These securities are held by Caxton Advantage Life Sciences Fund, L.P. The Reporting Person is (i) a Managing Director of Caxton Advantage Venture Partners, L.P., which is the General Partner of Caxton Advantage Life Sciences Fund, L.P. and (ii) a member of Advantage Life Sciences Partners LLC. Caxton Advantage Venture Partners, L.P. has voting and investment power with respect to such shares. Decisions by Caxton Advantage Venture Partners, L.P. with respect to such shares are made by Advantage Life Sciences Partners, LLC, the Managing General Partner of Caxton Advantage Venture Partners, L.P., together with the investment committee of Caxton Advantage Venture Partners, L.P. (continued in Footnote 3)
  3. The Reporting Person has the authority to take action on behalf of Advantage Life Sciences Partners, LLC as a member of Advantage Life Sciences Partners, LLC. The Reporting Person disclaims beneficial ownership, except to the extent of her proportionate pecuniary interest, either directly, or indirectly through Caxton Advantage Venture Partners, L.P. (or through any other entity which is a limited partner in Caxton Advantage Life Sciences Fund, L.P.), in Caxton Advantage Life Sciences Fund, L.P.